Thomson Reuters

Newport Vision CITM is the critical competitive intelligence and global business development system from Thomson, the industry authority on the global generics market.

Created specifically for research-based innovator, specialty and niche-brand pharmaceutical companies, it ensures you don't miss the developing generic competition that can impact your sales, or the opportunity that can build on your strengths.

Powerful integrated global information with unique analysis.

With Newport Vision CI, you can:

• Identify the likely source, timing and impact of generic competition on your branded products.
• Detect and interpret the earliest signs of alternative form and polymorph development and API manufacture.
• Identify and evaluate global niche brands and candidate products for acquisition or licensing.
• Determine if there are likely to be no generics, saving costly and perhaps needless line extension programs.
• Gather all the facts, before you hire costly specialist investigative firms and outside counsel.

Why choose Newport Vision CI?

• Unique strategic intelligence. Newport Vision CI incorporates the unique strategic intelligence and powerful competitive analysis that is only available from Thomson Scientific. It continually tracks, monitors and expertly analyzes ongoing developments in more than 10,000 launched products and 20,000 companies operating in the global pharmaceutical market.
• Be alert to potential generic activity. Its proven analytics can warn of potential generic activity four to seven years ahead of loss of exclusivity.
• Sophisticated targeting capabilities. Newport Vision CI can help you to identify, profile and evaluate licensing, acquisition and partnership opportunities in launched and approved products worldwide.
• Discover niche opportunities. You can discover the niche opportunities that match your strategic needs and unique strengths in research, sales or marketing.

• Sales, launch, approval and regulatory data for more than 10,000 launched products.
• Profiles of more than 20,000 companies and corporate groups, including subsidiary, launch, approvals, regulatory filings and APIs manufactured.
• Unique, early API manufacturing intelligence, the earliest and most reliable indicator of potential generic competition.
• Detailed manufacturing capabilities for an increasing number of sites.
• Alerting on key changes in products and companies, including new regulatory filings and approvals.
• Worldwide patent families and individual patents for more than 90 countries.
• Comprehensive Supplementary Protection Certificate (SPC) data for Europe.
• Projected loss of exclusivity dates for US and EEC markets.
• Sales figures by molecule and by dosage form for major world market regions, including two-year sales history.
• Current retail and hospital dose pack pricing for each dose form and strength of all products in more than 65 countries.
• Paragraph IV patent challenges commentaries, including company identities, FTF and status of litigation for more than 190 products.
• Product launch and first market authorization data, country-by-country.
• Orange book approved dose forms, US Drug Master Files, EU Certificates of Suitability and FDA warning letters and issues.
• Labeling and prescribing data for more than 1,800 unique products.
• Chemical structure diagram and details of alternative structures for thousands of products.
• Powerful indexing and searching of products according to FDA approved indication and technology class.